Photonic Gateway accommodating all types of wavelength paths for digital-coherent and IM-DD user terminals in all-photonic metro-access converged networks
Journal of Optical Communications and Networking · 01.03.2024 · 16 (3) · 304
DOI: 10.1364/jocn.503093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Optical Communications and Networking, online erschienen am 16.02.2024. Verfasst von Shin Kaneko und 5 weiteren Autor:innen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
In access and metro networks, there is increasing demand for guaranteed wide-bandwidth and stringent/deterministic end-to-end latency characteristics. Converging these networks by expanding dense wavelength-division-multiplexed metro networks to access areas is a promising approach to satisfy this demand. An All-Photonics Metro-Access Converged Network (APN) dynamically and flexibly provides a wavelength connection between any two points including user premises. This evolution in network architecture presents some technical challenges. First, from the access-node architecture viewpoint, conventional reconfigurable optical add/drop multiplexers (ROADMs) do not have functions for remote and in-channel user-terminal (UT) control or turn-back connection within the access area. Therefore, the APN cannot be achieved by simply adopting ROADMs as access nodes, which are defined as Photonic Gateways. Remote and in-channel UT controls are required to control the endpoints of a wavelength path beyond the carrier control-plane network. These types of control should be independent of the protocol and modulation/detection method for the main signal. In addition, the Photonic Gateway must flexibly and efficiently support a new type of wavelength path, specifically a turn-back connection within the access area, due to metro/access convergence. Second, from the viewpoint of the process for dynamic wavelength-path provisioning, the APN controller should autonomously discover physical connectivity between a UT and the Photonic Gateway connected via field access fibers. This paper proposes a novel Photonic Gateway architecture that flexibly and scalably provides various UTs with direct optical connections including turn-back configurations. This paper also proposes a method that autonomously recognizes physical connections between newly connected UTs and the Photonic Gateway. The proposed architecture and method are experimentally verified based on all types of wavelength-path provisioning that take at most 72 s using Photonic Gateway prototypes, 100-Gb/s digital-coherent UTs, and 10-Gb/s intensity-modulation direct-detection UTs. All types of wavelength paths that are provided over the APN architecture are considered including a turn-back connection between two UTs within the same access area and connections between two UTs that traverse the metro area with or without optical/electrical conversion.
Zitieren
APA
Kaneko, S., Yoshino, M., Shibata, N., Igarashi, R., Kani, J., & Yoshida, T. (2024). Photonic Gateway accommodating all types of wavelength paths for digital-coherent and IM-DD user terminals in all-photonic metro-access converged networks. Journal of Optical Communications and Networking, 16(3), 304. https://doi.org/10.1364/jocn.503093
Vancouver
Kaneko S, Yoshino M, Shibata N, Igarashi R, Kani J, Yoshida T. Photonic Gateway accommodating all types of wavelength paths for digital-coherent and IM-DD user terminals in all-photonic metro-access converged networks. Journal of Optical Communications and Networking. 2024;16(3):304. doi:10.1364/jocn.503093
BibTeX
@article{Kaneko2024,
author = {Kaneko, Shin and Yoshino, Manabu and Shibata, Naotaka and Igarashi, Ryo and Kani, Jun-ichi and Yoshida, Tomoaki},
title = {Photonic Gateway accommodating all types of wavelength paths for digital-coherent and IM-DD user terminals in all-photonic metro-access converged networks},
journal = {Journal of Optical Communications and Networking},
year = {2024},
volume = {16},
number = {3},
pages = {304},
doi = {10.1364/jocn.503093}
}
EUVIMED